Eyeworld

IYUZEH is a trademark of Laboratoires Théa. Copyright ©2023 Thea Pharma Inc. | All Rights Reserved. | PRC-IYZ-1410-v3 09.2023 INDICATIONS AND USAGE IYUZEH™ is a prostaglandin analogue indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS Known hypersensitivity to latanoprost or any other ingredients in this product. WARNINGS AND PRECAUTIONS Pigmentation: Topical latanoprost ophthalmic products, including IYUZEH™ have been reported to cause changes to pigmented tissues. The most frequently reported changes have been increased pigmentation of the iris, periorbital tissue (eyelid), and eyelashes. Pigmentation is expected to increase as long as latanoprost is administered. The pigmentation change is due to increased melanin content in the melanocytes rather than to an increase in the number of melanocytes. After discontinuation of latanoprost, pigmentation of the iris is likely to be permanent, while pigmentation of the periorbital tissue and eyelash changes have been reported to be reversible in some patients. Patients who receive treatment should be informed of the possibility of increased pigmentation. The long-term effects of increased pigmentation are not known. Iris color change may not be noticeable for several months to years. Typically, the brown pigmentation around the pupil spreads concentrically towards the periphery of the iris and the entire iris or parts of the iris become more brownish. Neither nevi nor freckles of the iris appear to be affected by treatment. While treatment with IYUZEH™ can be continued in patients who develop noticeably increased iris pigmentation, these patients should be examined regularly. Eyelash Changes: Latanoprost ophthalmic products, including IYUZEH™ may gradually change eyelashes and vellus hair in the treated eye; these changes include increased length, thickness, pigmentation, the number of lashes or hairs, and misdirected growth of eyelashes. Eyelash changes are usually reversible upon discontinuation of treatment. Intraocular Infl ammation: IYUZEH™ should be used with caution in patients with a history of intraocular infl ammation (iritis/uveitis) and should generally not be used in patients with active intraocular infl ammation because infl ammation may be exacerbated. Macular Edema: Macular edema, including cystoid macular edema, has been reported during treatment with latanoprost ophthalmic products, including IYUZEH™. IYUZEH™ should be used with caution in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for macular edema. Herpetic Keratitis: Reactivation of herpes simplex keratitis has been reported during treatment with latanoprost. IYUZEH™ should be used with caution in patients with a history of herpetic keratitis. IYUZEH™ should be avoided in cases of active herpes simplex keratitis because infl ammation may be exacerbated. Contact Lens Use: Contact lenses should be removed prior to the administration of IYUZEH™ and may be reinserted 15 minutes after administration. ADVERSE REAC TIONS The following adverse reactions have been reported with the use of topical latanoprost products: iris pigmentation changes, eyelid skin darkening, eyelash changes (increased length, thickness, pigmentation, and number of lashes), intraocular infl ammation (iritis/uveitis), and macular edema, including cystoid macular edema. DRUG INTERAC TIONS The combined use of two or more prostaglandins, or prostaglandin analogs including IYUZEH™ is not recommended. It has been shown that administration of these prostaglandin drug products more than once daily may decrease the IOP lowering effect or cause paradoxical elevations in IOP. Please see full Prescribing Information at www.iyuzeh.com and Brief Summary on the next page. Explore the power of preser vative -free latanoprost at iyuzeh.com We owe it to our patients with elevated intraocular pressure, with open-angle glaucoma or ocular hypertension to provide a new evidence-based approach. It is an extremely exciting time to prescribe IYUZEH™ for my patients. Monique M. Barbour, MD, MHA, FAAO Dr. Barbour is a paid consultant of Thea Pharma Inc. IYUZEH ™ (latanoprost ophthalmic solution) 0.005% is the fi rst and only preservative-free latanoprost for patients with primary open-angle glaucoma (POAG) and ocular hypertension (OHT).

• Blank Page
• Blank Page (1)